You did gomer!! What your selling is a goner!!! Baaahaaa
-
Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page
Fanapt Falls Flat! Link from the Street.com
- Thread starter Anonymous
- Start date
-
- Tags
- None
You did gomer!! What your selling is a goner!!! Baaahaaa
Psych Account Managers, what do they do? I am very serious when I say that mine has only met about half my customers.
How can anyone justify the existence of this job?
How can anyone justify the existence of this job?
Yeah, you guys are rocking the Fanapt! Dripping with sarcasm!
This is the key to the future of Fanapt. In reality, there IS no future!
AstraZenca has now announced they are cutting 1150 reps nationwide. How are you going to sell Fanapt when even the big boys (Seroquel) realize the end is near................
Mostly because of Crestor and Lipitor's generic entry, not Seroquel.
What were Fanapt sales in the third quarter? Any improvement?
Wow - this thread has turned into a rope ! Unfortunately, there is a lot of finger pointing going on.
First, a few things to think about-
1.) the big sales antipsychotics going generic will not have an effect on the Fanapt sales curve. Recall that Clozaril had 4 generic clozapines on the market and it held its share for 8 years losing less than 0.5 pt/share per month over that time period. It still beats Fanapt in $$$.
2.) Stop blaming the reps - they really didn't have a good strategy to begin with. Management decided to populate itself with experienced managers who sold the first line anti-psychotics like Zyprexa and Risperdal. Problem is, Fanapt required a strategy to place it as a alternative antipsychotic - possible third line. Sure, you don't get the big pop in the beginning but you establish credibility with your customers and patients are always changing meds- so you eventually do get a trial on most patients.
3) Does the competition worry about Fanapt. It fell off the radar screen a long time ago. Not even a consideration.
Advice: Stop blaming each other / re-think the strategy / use small, specialty force tactics to position it as third line therapy / treat yourselves and customers with respect.
Good Luck!
First, a few things to think about-
1.) the big sales antipsychotics going generic will not have an effect on the Fanapt sales curve. Recall that Clozaril had 4 generic clozapines on the market and it held its share for 8 years losing less than 0.5 pt/share per month over that time period. It still beats Fanapt in $$$.
2.) Stop blaming the reps - they really didn't have a good strategy to begin with. Management decided to populate itself with experienced managers who sold the first line anti-psychotics like Zyprexa and Risperdal. Problem is, Fanapt required a strategy to place it as a alternative antipsychotic - possible third line. Sure, you don't get the big pop in the beginning but you establish credibility with your customers and patients are always changing meds- so you eventually do get a trial on most patients.
3) Does the competition worry about Fanapt. It fell off the radar screen a long time ago. Not even a consideration.
Advice: Stop blaming each other / re-think the strategy / use small, specialty force tactics to position it as third line therapy / treat yourselves and customers with respect.
Good Luck!
Your Clozaril example is poor. The pharmaceutical world and more specifically the antipsychotic world have changed so much this example has no bearing in todays market. From state budget situations to crowded market with generics. Oh, and a drug which offers no real advantages over others on market and the most complicated dosing of all. I've done well with it only due to relationships with prescribers.
Wow, the Tekturna news today is even worse than miserable Fanapt sales! The layoff on May 1, 2012 is going to be even more severe than we thought!
What? I was hoping I could leave the Fanapt sales force and transition over to selling Tekturna and Valturna!
May 1, 2012? Really? With the recent Tekturna news the layoff is now probably February 1, 2012!
Q3 sales were $12.2m versus $7.5m in Q2.
Based on current script data, looks like current run-rate is just over $1m/week.
remember even with 450 million dollars per year. The Tekturna brand has not turned a profit.
12 million per qrt is not enough to save you
12 million per qrt is not enough to save you
After deducting payments to Vanda/Titan and medicaid rebates looks much worse.
Forgot about this. Since I am sure this is true, is there really any reason to keep a Fanapt sales force?